RegeneRx Biopharmaceuticals, Inc. has received notification that the State Intellectual Property Office of the People’s Republic of China (SIPO) has allowed its first patent application for the Company’s Thymosin beta 4 (TB4), wound healing technology platform.
RegeneRx president and CEO J.J. Finkelstein: “We are very pleased to be advancing our intellectual property portfolio in this important market. China, of course, represents one of the largest and fastest growing pharmaceutical markets in the world; we look forward to receiving additional patents in China in the future and addressing a number of potential opportunities in that market.”
Read here more.
